M&A / Deals Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia PharmaphorumEli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.M&A / DealsOncologyRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped. M&A / DealsOncologyRead full story Post navigation Previous: The Omnichannel Gap: Building the CRM of the Future for Patient ServicesNext: UK Knowledge Quarter welcomes Boehringer Ingelheim AI accelerator Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026